Zetia Cost in Illinois 2026: What You'll Actually Pay for Ezetimibe

What Does Zetia Actually Cost in Illinois in 2026?

The price you pay for ezetimibe in Illinois depends almost entirely on whether you choose brand-name Zetia or a generic, and which payment method you use. Brand Zetia carries a manufacturer list price near $380 per month. Generic ezetimibe 10 mg, available from multiple manufacturers since the patent expired, typically costs about $15 per month at Illinois retail pharmacies when purchased with a discount card.

The $365-per-month gap between brand and generic is not a rounding error. It reflects the standard dynamic in post-patent small-molecule drugs, where brand manufacturers maintain high list prices while generic competition drives down the actual market price substantially. The FDA approved ezetimibe (brand name Zetia) in 2002 for adjunct treatment of primary hypercholesterolemia, either alone or combined with a statin [1]. Since generic entry, prescription volume has shifted heavily toward generics.

For patients paying cash, GoodRx and similar platforms routinely show ezetimibe 10 mg (30 tablets) at $10 to $18 at Walgreens, CVS, Costco, Jewel-Osco, and independent pharmacies across Chicago, Springfield, Rockford, and other Illinois metro areas. Calling ahead to compare pharmacy prices in your ZIP code takes about five minutes and can confirm the lowest local option [2].

The clinical rationale for the medication is well established. IMPROVE-IT (N=18,144), published in the New England Journal of Medicine in 2015, demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by an absolute 2.0 percentage points (relative risk reduction 6.4%, P<0.001) over seven years compared with simvastatin alone [3]. That evidence base, combined with the low generic price, makes ezetimibe one of the most cost-effective second-line lipid-lowering agents available in Illinois today.

How Does Illinois Medicaid Cover Ezetimibe?

Illinois Medicaid (administered through HFS managed-care plans) covers ezetimibe for hyperlipidemia, but requires prior authorization (PA) before dispensing. The PA process typically asks your prescriber to document that a statin was tried or is contraindicated, and that ezetimibe is medically necessary for LDL-C management.

Once PA is approved, Illinois Medicaid beneficiaries generally pay $0 to $4 per 30-day supply under the program's generic drug cost-sharing structure. The Illinois Department of Healthcare and Family Services maintains the preferred drug list (PDL), and ezetimibe sits on the PDL as a non-preferred generic requiring PA rather than a flat-excluded product [4]. That distinction matters: your prescriber can complete a PA request through the HFS online portal, and approval timelines are commonly 24 to 72 hours for straightforward hyperlipidemia cases.

Managed-care plans contracting with Illinois Medicaid, including Molina Healthcare of Illinois, Meridian Health Plan, and Blue Cross Community Health Plans, each operate their own PA forms, but all must follow HFS coverage policy on ezetimibe. Ask your prescriber's office which form the plan requires before your appointment to avoid delays.

The American College of Cardiology and American Heart Association 2018 cholesterol guidelines state: "In patients with clinical ASCVD, if maximally tolerated statin therapy does not lower LDL-C sufficiently, adding ezetimibe is reasonable" [5]. That language gives Illinois Medicaid PA reviewers a strong clinical basis to approve requests that arrive with statin intolerance documentation or inadequate LDL-C response data.

Which Insurance Plans Cover Zetia in Illinois, and at What Tier?

Most commercial insurance plans sold in Illinois cover generic ezetimibe 10 mg at Tier 1 (preferred generic) or Tier 2 (non-preferred generic), meaning copays typically range from $0 to $15 per month. Brand-name Zetia, when it appears on formularies at all, generally lands at Tier 3 or Tier 4, where cost-sharing can reach $50 to $100 or more per fill [6].

Illinois-based employer plans and ACA marketplace plans administered by BCBS Illinois, Aetna, Cigna, and UnitedHealthcare all include generic ezetimibe in standard formularies as of 2026. Tier placement, however, varies by plan year and specific contract. Checking your plan's drug formulary on its member portal, or calling the pharmacy benefits number on your insurance card, gives you the exact tier and copay for your specific policy.

Medicare Part D plans available in Illinois cover generic ezetimibe broadly. In the 2026 Part D redesign under the Inflation Reduction Act, out-of-pocket drug spending is capped at $2,000 annually for Medicare beneficiaries, which meaningfully limits exposure even for patients on multiple medications [7]. The $2,000 cap means that even if your Part D plan places ezetimibe at a higher tier initially, your total annual out-of-pocket liability for all Part D drugs combined cannot exceed that threshold.

If your insurer denies coverage or places ezetimibe at an unaffordable tier, your prescriber can file a formulary exception request citing the ACC/AHA guidelines and your LDL-C lab values. Denials that follow are appealable under Illinois insurance law within 60 days of the denial notice [8].

Is Compounded Ezetimibe Legal in Illinois?

Compounded ezetimibe is legal in Illinois when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies, and Illinois-licensed compounders operating within 503A rules may prepare ezetimibe formulations as long as a practitioner-patient relationship exists and the compound is not commercially available in the exact form prescribed [9].

503A pharmacies differ from 503B outsourcing facilities, which produce larger batches for hospital or clinical use. For an individual Illinois patient, the relevant pathway is 503A: your prescriber writes a patient-specific prescription, the pharmacy compounds the formulation (commonly a capsule at a custom dose or combined with another agent like a statin or coenzyme Q10), and dispenses it to you directly [10].

The cost advantage at some compounding programs can be substantial. Where a telehealth platform or clinic bundles compounded ezetimibe into a membership fee covering the prescriber visit, labs, and medication, the direct out-of-pocket cost for the drug itself may be $0 per month. That pricing model is not universal. Many 503A compounders charge $30 to $80 per month for compounded ezetimibe capsules when billed directly, depending on dose and formulation complexity.

Illinois pharmacy law, enforced by the Illinois Department of Financial and Professional Regulation (IDFPR), requires that compounding pharmacies hold an active pharmacy license and that compounding be done pursuant to a valid prescription [11]. Patients should confirm that any compounding pharmacy they use holds a current Illinois license, which is searchable through the IDFPR public license lookup tool.

Can You Get Ezetimibe via Telehealth in Illinois?

Telehealth prescribing of ezetimibe is fully legal in Illinois. State law and the Illinois Telehealth Act allow licensed physicians, nurse practitioners, and physician assistants to evaluate patients via synchronous audio-video visits and issue valid prescriptions, including controlled and non-controlled drugs, without a prior in-person visit [12].

For ezetimibe specifically, this means a cardiologist, internist, or lipid specialist can review your LDL-C panel, statin history, and cardiovascular risk factors during a telehealth visit and prescribe ezetimibe 10 mg the same day. The prescription transmits electronically to your Illinois pharmacy of choice or, if you are receiving compounded ezetimibe, to a licensed compounding pharmacy.

Telehealth platforms operating in Illinois that focus on metabolic and cardiovascular health include HealthRX and several cardiology-specific services. Visit costs vary from $0 (covered by insurance) to $100 to $200 for a cash-pay initial consultation. Annual lipid panel monitoring, which the ACC/AHA guidelines recommend at four to twelve weeks after initiating or adjusting lipid therapy and then annually, can often be ordered through the telehealth visit and completed at a local Illinois LabCorp or Quest Diagnostics draw site [13].

One practical note: Illinois Medicaid telehealth coverage for outpatient medical visits was made permanent following the COVID-19 public health emergency, meaning Medicaid beneficiaries can use telehealth to obtain ezetimibe prescriptions without additional barriers [14].

What Are the Cheapest Ways to Get Ezetimibe in Illinois?

The cheapest realistic option for most Illinois patients without insurance is generic ezetimibe 10 mg purchased with a GoodRx, RxSaver, or SingleCare coupon at a high-volume pharmacy. Prices at Costco Pharmacy (available without a Costco membership for pharmacy services in Illinois) and Mark Cuban's Cost Plus Drugs platform commonly come in at $6 to $15 for 30 tablets [15].

Cost Plus Drugs lists ezetimibe 10 mg at a fixed transparent price that has run below $15 for a 30-day supply, though prices are subject to change. The platform ships to Illinois addresses. For patients who prefer local pickup, Costco Pharmacy in Illinois locations (Bolingbrook, Schaumburg, Orland Park, and others) consistently ranks among the lowest-cost retail options for generic ezetimibe.

For insured patients, the cheapest route is confirming that your plan covers the generic (not brand) and that your prescription is written for ezetimibe 10 mg generically. Asking your prescriber to write "dispense as generic" or "DAW-0" on the prescription ensures the pharmacist substitutes the generic automatically.

Illinois residents who cannot afford any out-of-pocket cost may qualify for the following programs. The Merck Patient Assistance Program covers brand Zetia for uninsured or underinsured patients meeting income thresholds, generally at or below 400% of the federal poverty level [16]. NeedyMeds.org maintains an Illinois-specific database of pharmaceutical assistance programs updated quarterly. The Illinois Department on Aging operates the Community Care Program and pharmaceutical assistance resources for residents age 60 and older [17].

The HealthRX Ezetimibe Cost Decision Framework for Illinois patients works as follows. First, confirm whether you have any insurance (commercial, Medicaid, or Medicare Part D). If yes, check the formulary tier for generic ezetimibe and calculate your copay. If your copay exceeds $20 per month, request a formulary exception or tier exception in writing. If you have no insurance, price generic ezetimibe with GoodRx at three local pharmacies and Cost Plus Drugs before filling. If cost remains prohibitive after those steps, ask your prescriber about a 503A compounding pharmacy or a telehealth platform that bundles medication cost into the visit fee. If you meet income criteria, apply to the Merck Patient Assistance Program before the prescription is written, as retroactive enrollment is not available.

How Do Merck Savings Cards and Generic Manufacturer Coupons Work in Illinois?

Merck offers a Zetia savings card for commercially insured patients in Illinois that can reduce the brand-name copay to as low as $10 per fill, subject to a monthly maximum savings cap and eligibility restrictions [16]. The card is not valid for patients enrolled in any federal or state government insurance program, including Illinois Medicaid, Medicare Part D, or CHIP. That restriction is federally mandated and applies nationwide.

Generic ezetimibe manufacturers do not routinely offer branded savings cards, but the generic's low cash price largely makes those programs unnecessary. When generic ezetimibe costs $10 to $15 per month at retail, the marginal value of a manufacturer coupon is minimal.

For Illinois patients on Medicare Part D who find themselves in a coverage gap or paying high cost-sharing, pharmaceutical manufacturer patient assistance programs (separate from savings cards) may provide medication at no cost. Merck's program accepts Medicare patients who meet income criteria, unlike the savings card [16]. Applications require income verification and a completed physician attestation. Processing takes two to four weeks on average.

Illinois also participates in the Rx Outreach program and the Partnership for Prescription Assistance, both of which maintain formularies that include ezetimibe and accept Illinois residents [17].

What Do the Clinical Guidelines Say About Ezetimibe Dosing and Monitoring?

Ezetimibe 10 mg once daily is the only approved dose for adults in the United States, as specified in the FDA-approved prescribing information [1]. The drug works by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing cholesterol absorption by roughly 54% compared with placebo [18]. That mechanism is entirely distinct from statins, which is why the combination is additive rather than redundant.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol recommends ezetimibe as the preferred second-line agent after statin therapy for patients with very high cardiovascular risk who do not reach LDL-C goals on maximally tolerated statin therapy [5]. The guideline sets an LDL-C goal of <70 mg/dL for very high-risk patients and <55 mg/dL for patients with recent acute coronary syndrome, both thresholds supported by IMPROVE-IT and subsequent PCSK9 inhibitor trials [3].

Monitoring after starting ezetimibe includes a fasting lipid panel at four to twelve weeks post-initiation, then annually if stable, per ACC/AHA guidance [13]. Liver function testing is not routinely required for ezetimibe alone, unlike higher-dose statin regimens. The most common adverse effects in clinical trials were upper respiratory infection (4.3% vs. 2.7% placebo) and diarrhea (4.1% vs. 3.7% placebo), both mild and transient [18].

Ezetimibe is pregnancy category C and is contraindicated during pregnancy and lactation when used in combination with a statin [1]. For women of reproductive age in Illinois seeking lipid therapy, a discussion of contraceptive planning is standard practice before initiating any statin-ezetimibe combination.

How Does Ezetimibe Compare with PCSK9 Inhibitors on Cost in Illinois?

Ezetimibe is dramatically cheaper than PCSK9 inhibitors in Illinois in 2026. Evolocumab (Repatha) and alirocumab (Praluent) carry list prices of $450 to $650 per month, though manufacturer savings programs and pharmacy benefit negotiations can reduce that substantially for some insured patients [19]. Generic ezetimibe at $15 per month is roughly 30-fold cheaper at list price.

Clinically, PCSK9 inhibitors produce larger absolute LDL-C reductions, typically 50 to 60% on top of statin therapy, compared with ezetimibe's 15 to 25% additional LDL-C reduction [20]. For patients with familial hypercholesterolemia or established ASCVD whose LDL-C remains above 70 mg/dL despite statin plus ezetimibe, PCSK9 inhibitors are the guideline-recommended next step [5]. For patients who need modest incremental LDL-C lowering after a statin, ezetimibe at $15 per month is the economically rational first addition.

The FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% relative to placebo over 2.2 years in statin-treated patients (P<0.001) [19]. The comparable IMPROVE-IT data for ezetimibe, 6.4% relative risk reduction over seven years, shows a smaller effect size but with a cost difference that makes ezetimibe far more accessible for Illinois patients without strong insurance coverage [3].

Illinois-Specific Pharmacy Access and Distribution Notes

Illinois has no state-level drug price cap or maximum out-of-pocket law specific to ezetimibe beyond standard ACA and Medicaid regulations. The Illinois Insurance Code requires that insured plans cover at least one drug in each therapeutic class represented on the Essential Health Benefits benchmark plan, which includes lipid-lowering agents. Generic ezetimibe satisfies that requirement for virtually all Illinois-regulated plans [8].

Illinois 340B covered entities, including federally qualified health centers (FQHCs), Ryan White HIV/AIDS Program grantees, and disproportionate share hospitals, can dispense ezetimibe to eligible patients at 340B prices, which are typically below generic retail cost. Patients receiving care at Chicago FQHCs such as Erie Family Health Centers, Near North Health, and Heartland Health Centers may be eligible for 340B-priced ezetimibe if they are uninsured or underinsured [21].

Mail-order pharmacy (90-day supply) through commercial insurance plans commonly reduces the per-unit cost by 10 to 20% compared with 30-day retail fills. For a maintenance medication like ezetimibe, switching to 90-day mail order can save $2 to $5 per month at current generic prices, a modest but real reduction.

The FDA bioequivalence standard for generic drugs requires that the generic deliver 80 to 125% of the reference drug's bioavailability (AUC and Cmax) within a 90% confidence interval [22]. All FDA-approved generic ezetimibe products meet this standard, meaning clinical substitution of one manufacturer's tablets for another does not require dose adjustment.